GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT05797948 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Zanubrutinib
DRUG: Lenalidomide
DRUG: CD19/CD22 CAR-T
DRUG: Azacitidine For Injection
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

The First Affiliated Hospital of Soochow University